|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wright JD, Shah M, Mathew L, Burke WM,
Culhane J, Goldman N, Schiff PB and Herzog TJ: Fertility
preservation in young women with epithelial ovarian cancer. Cancer.
115:4118–4126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Nagell JR Jr and Hoff JT: Transvaginal
ultrasonography in ovarian cancer screening: Current perspectives.
Int J Womens Health. 6:25–33. 2013. View Article : Google Scholar :
|
|
4
|
Leung F, Diamandis EP and Kulasingam V:
Ovarian cancer biomarkers: Current state and future implications
from high-throughput technologies. Adv Clin Chem. 66:25–77. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jacobs I and Bast RC Jr: The CA 125
tumour-associated antigen: A review of the literature. Hum Reprod.
4:1–12. 1989.PubMed/NCBI
|
|
6
|
Cohen JG, White M, Cruz A and
Farias-Eisner R: In 2014, can we do better than CA125 in the early
detection of ovarian cancer? World J Biol Chem. 5:286–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berek JS and Bast RC Jr: Ovarian cancer
screening. The use of serial complementary tumor markers to improve
sensitivity and specificity for early detection. Cancer. 76(Suppl
10): S2092–S2096. 1995. View Article : Google Scholar
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neal CS, Michael MZ, Pimlott LK, Yong TY,
Li JY and Gleadle JM: Circulating microRNA expression is reduced in
chronic kidney disease. Nephrol Dial Transplant. 26:3794–3802.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lorenzen JM, Volkmann I, Fiedler J,
Schmidt M, Scheffner I, Haller H, Gwinner W and Thum T: Urinary
miR-210 as a mediator of acute T-cell mediated rejection in renal
allograft recipients. Am J Transplant. 11:2221–2227. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanke M, Hoefig K, Merz H, Feller AC,
Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust
methodology to study urine microRNA as tumor marker: microRNA-126
and microRNA-182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010. View Article : Google Scholar
|
|
16
|
Wang G, Tam LS, Li EK, Kwan BC, Chow KM,
Luk CC, Li PK and Szeto CC: Serum and urinary cell-free miR-146a
and miR-155 in patients with systemic lupus erythematosus. J
Rheumatol. 37:2516–2522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo Y, Wang C, Chen X, Zhong T, Cai X,
Chen S, Shi Y, Hu J, Guan X, Xia Z, et al: Increased serum and
urinary microRNAs in children with idiopathic nephrotic syndrome.
Clin Chem. 59:658–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taylor DD and Gercel-Taylor C: MicroRNA
signatures of tumor-derived exosomes as diagnostic biomarkers of
ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar
|
|
21
|
Jiang X, Du L, Wang L, Li J, Liu Y, Zheng
G, Qu A, Zhang X, Pan H, Yang Y, et al: Serum microRNA expression
signatures identified from genome-wide microRNA profiling serve as
novel noninvasive biomarkers for diagnosis and recurrence of
bladder cancer. Int J Cancer. 136:854–862. 2015. View Article : Google Scholar
|
|
22
|
Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao
J, Wang Y, Yang S and Pu P: Analysis of hsa-miR-30a-5p expression
in human gliomas. Pathol Oncol Res. 19:405–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vlassov AV, Magdaleno S, Setterquist R and
Conrad R: Exosomes: Current knowledge of their composition,
biological functions, and diagnostic and therapeutic potentials.
Biochim Biophys Acta. 1820:940–948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu Y, Li M, Wang T, Liang Y, Zhong Z, Wang
X, Zhou Q, Chen L, Lang Q, He Z, et al: Lactation-related microRNA
expression profiles of porcine breast milk exosomes. PLoS One.
7:e436912012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keller S, Ridinger J, Rupp AK, Janssen JW
and Altevogt P: Body fluid derived exosomes as a novel template for
clinical diagnostics. J Transl Med. 9:862011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xi Y, Formentini A, Chien M, Weir DB,
Russo JJ and Ju J, Kornmann M and Ju J: Prognostic values of
microRNAs in colorectal cancer. Biomark Insights. 2:113–121.
2006.
|
|
27
|
Visone R, Pallante P, Vecchione A,
Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V,
Borbone E, et al: Specific microRNAs are downregulated in human
thyroid anaplastic carcinomas. Oncogene. 26:7590–7595. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Zhang Y, Zhang Y, Ding J, Wu K and
Fan D: Survival prediction of gastric cancer by a seven-microRNA
signature. Gut. 59:579–585. 2010. View Article : Google Scholar
|
|
29
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jia Z, Wang K, Wang G, Zhang A and Pu P:
MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth
by targeting SEPT7. PLoS One. 8:e550082013. View Article : Google Scholar : PubMed/NCBI
|
